Compare Cytokinetics Inc (CYTK) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Hilton Hotels Corporation Common Stock trades at $323.76 (market cap $72.76B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 8.4× Cytokinetics Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Hilton Hotels Corporation Common Stock for 138 Days on average.
| CYTK | HLT | |
|---|---|---|
Market Cap | $8.62B | $72.76B |
Volume | 2,594,626 | 1,148,634 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $350.22 |
52-Week Low | $54.76 | $256.96 |
Typical Hold Time | 19 Days | 138 Days |
Enterprise Value | $8.72B | $85.78B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Hilton Worldwide (HLT) trades at $320.50, down 0.65% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates consistent revenue growth, reaching $12.04 billion in 2025, with earnings beating expectations for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with 57% buy ratings and a $348.11 consensus price target representing 8.6% upside potential. Recent institutional buying activity and upcoming Q3 2026 earnings on October 27 provide near-term catalysts.
Hilton presents a compelling investment case with robust fundamentals and positive momentum, though elevated valuation metrics (P/E of 47.07) and increasing debt levels warrant caution. The stock's technical positioning near key support at $318 suggests potential for continued upward movement if earnings momentum persists, while institutional accumulation and strong travel demand support the bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
